Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition

Basal-like breast cancers (BLBC) are aggressive breast cancers that respond poorly to targeted therapies and chemotherapies. In order to define therapeutically targetable subsets of BLBC we examined two markers: cyclin E1 and BRCA1 loss. In high grade serous ovarian cancer (HGSOC) these markers are...

Descripción completa

Detalles Bibliográficos
Autores principales: Aziz, Diar, Portman, Neil, Fernandez, Kristine J., Lee, Christine, Alexandrou, Sarah, Llop-Guevara, Alba, Phan, Zoe, Yong, Aliza, Wilkinson, Ashleigh, Sergio, C. Marcelo, Ferraro, Danielle, Etemadmoghadam, Dariush, Bowtell, David D., Serra, Violeta, Waring, Paul, Lim, Elgene, Caldon, C. Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408175/
https://www.ncbi.nlm.nih.gov/pubmed/34465787
http://dx.doi.org/10.1038/s41523-021-00312-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408175/
https://www.ncbi.nlm.nih.gov/pubmed/34465787
http://dx.doi.org/10.1038/s41523-021-00312-x

Ejemplares similares